Monitoring of early humoral immunity to identify lung recipients at risk for development of serious infections: A multicenter prospective study
| Autor: | Sandra García, C. Bravo, Javier Carbone, Joaquin Luis Navarro, Carmen Morales, Sonia Lopez, M. Jaramillo, Elizabeth Sarmiento, L. Calahorra, Marcos López-Hoyos, Alicia de Pablos, Rosalía Laporta, Piedad Ussetti, I. Ezzahouri, Amparo Solé, José M. Cifrián |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Male medicine.medical_treatment 030230 surgery Hypogammaglobulinemia 0302 clinical medicine Agammaglobulinemia Risk Factors B-Cell Activating Factor risk factors Prospective Studies Cross Infection biology lobulinemia Bacterial Infections Middle Aged Cytomegalovirus Infections BAFF Female Antibody Cardiology and Cardiovascular Medicine Lung Transplantation Pulmonary and Respiratory Medicine Adult Congenital cytomegalovirus infection Opportunistic Infections 03 medical and health sciences medicine lung transplantation Lung transplantation Humans Risk factor Aged Monitoring Physiologic Transplantation business.industry Odds ratio medicine.disease infection Immunity Humoral 030104 developmental biology Early Diagnosis Mycoses Immunology Humoral immunity Antibody Formation biology.protein hypogammag Surgery business Biomarkers |
| Zdroj: | The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe instname |
| ISSN: | 1053-2498 |
| Popis: | BACKGROUND: Infection is still a leading cause of death during the first year after lung transplantation. We performed a multicenter study among teaching hospitals to assess monitoring of early humoral immunity as a means of identifying lung recipients at risk of serious infections. METHODS: We prospectively analyzed 82 adult lung recipients at 5 centers in Spain. Data were collected before transplantation and at 7 and 30 days after transplantation. Biomarkers included IgG, IgM, IgA, complement factors C3 and C4, titers of antibodies to pneumococcal polysaccharide antigens (IgG, IgA, IgM) and antibodies to cytomegalovirus (IgG), and serum B-cell activating factor (BAFF) levels. The clinical follow-up period lasted 6 months. Clinical outcomes were bacterial infections requiring intravenous anti-microbial agents, cytomegalovirus (CMV) disease, and fungal infections requiring therapy. RESULTS: We found that 33 patients (40.2%) developed at least 1 serious bacterial infection, 8 patients (9.8%) had CMV disease, and 10 patients (12.2%) had fungal infections. Lower IgM antibody levels against pneumococcal polysaccharide antigens at Day 7 (defined as |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|